Study Discovers Mutations That Cause Resistance to Lynparza, Similar Therapies

Study Discovers Mutations That Cause Resistance to Lynparza, Similar Therapies
Researchers have identified mutations in the poly (ADP-ribose) polymerase (PARP) gene that cause resistance to the cancer therapy Lynparza (olaparib) and other PARP inhibitors.  These mutations could help physicians predict which cancer patients will respond to the therapy and who will likely become resistant. With this insight, doctors can decide the most appropriate treatment approach. The study, “Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance,” was published in the journal Nature Communications. Lynparza, an oral medicine developed by AstraZeneca, is approved in the U.S for the treatment of HER2-negative, metastatic breast cancer patients who have mutations in the BRCA genes and have received prior chemotherapy treatment. The medicine is also approved as a maintenance treatment for advanced ovarian cancer. The compound is an inhibitor of PARP enzymes – par
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.